Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 167

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review

Sorokin, Alexey, Brown, Jennifer L., Thompson, Paul D. · 2007 · Atherosclerosis

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.atherosclerosis.2006.11.036

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 41

  1. Kaplan, 2005, Primary biliary cirrhosis, N Engl J Med, 353, 1261, 10.1056/NEJMra043898 · DOI · Paper page
  2. Corpechot, 2005, The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis, Gastroenterology, 128, 297, 10.1053/j.gastro.2004.11.009 · DOI · Paper page
  3. Metcalf, 1997, Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, Engl Int J Epidemiol, 26, 830, 10.1093/ije/26.4.830 · DOI · Paper page
  4. Boberg, 1998, Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population, Scand J Gastroenterol, 33, 99, 10.1080/00365529850166284 · DOI · Paper page
  5. Leuschner, 2000, Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment, Gut, 46, 121, 10.1136/gut.46.1.121 · DOI
  6. Leuschner, 2005, Ursodeoxycholic acid in the therapy for primary biliary cirrhosis: effects on progression and prognosis, Z Gastroenterol, 43, 1051, 10.1055/s-2005-858281 · DOI
  7. Gylling, 1995, Metabolism of cholesterol and low- and high-density lipoproteins in primary biliary cirrhosis: cholesterol absorption and synthesis related to lipoprotein levels and their kinetics, Hepatology, 21, 89
  8. Perales, 1994, Changes in the lipid profile in chronic hepatopathies, Med Clin (Barc), 102, 364
  9. Kosoglou, 2005, Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions, Clin Pharmacokinet, 44, 467, 10.2165/00003088-200544050-00002 · DOI · Paper page
  10. Chang, 2004, Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation, J Lipid Res, 45, 2116, 10.1194/jlr.M400229-JLR200 · DOI
  11. Manzato, 1976, Formation of lipoprotein-X. Its relationship to bile compounds, J Clin Invest, 57, 1248, 10.1172/JCI108393 · DOI
  12. Jahn, 1985, Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification, Gastroenterology, 89, 1266, 10.1016/0016-5085(85)90642-0 · DOI
  13. Rosenson, 1990, Hyperviscosity syndrome in a hypercholesterolemic patient with primary biliary cirrhosis, Gastroenterology, 98, 1351, 10.1016/0016-5085(90)90356-6 · DOI
  14. Walli, 1984, Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxy-3-methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes, and in the rat, J Clin Invest, 74, 867, 10.1172/JCI111504 · DOI
  15. Edwards, 1993, Lipoprotein-X fails to inhibit hydroxymethylglutaryl coenzyme A reductase in HepG2 cells, Metabolism, 42, 807, 10.1016/0026-0495(93)90051-O · doi:10.1016/0026-0495(93)90051-o
  16. Baldo-Enzi, 1988, Lipoprotein pattern and plasma lipoprotein lipase activities in patients with primary biliary cirrhosis. Relationship with increase of HDL2 fraction in Lp-X-positive and Lp-X-negative subjects, Digest Dis Sci, 33, 1201, 10.1007/BF01536666 · DOI · Paper page
  17. Miller, 1990, Dyslipoproteinaemia of liver disease, Baillieres Clin Endocrinol Metab, 4, 807, 10.1016/S0950-351X(05)80080-1 · DOI
  18. Eisenberg, 1984, High density lipoprotein metabolism, J Lipid Res, 25, 1017, 10.1016/S0022-2275(20)37713-0 · DOI · Paper page
  19. Owen, 1984, Abnormal high density lipoproteins from patients with liver disease regulate cholesterol metabolism in cultured human skin fibroblasts, J Lipid Res, 25, 919, 10.1016/S0022-2275(20)37730-0 · DOI
  20. Agorastos, 1978, Lecithin-cholesterol acyltransferase and the lipoprotein abnormalities of obstructive jaundice., Clin Sci Mol Med, 54, 369
  21. Muller, 1974, Hypertriglyceridaemia secondary to liver disease, Eur J Clin Invest, 4, 419, 10.1111/j.1365-2362.1974.tb00415.x · doi:10.1111/j.1365-2362.1974.tb00415.x
  22. Hiraoka, 1993, Decrease of hepatic triglyceride lipase levels and increase of cholesteryl ester transfer protein levels in patients with primary biliary cirrhosis: relationship to abnormalities in high-density lipoprotein, Hepatology, 18, 103, 10.1002/hep.1840180117 · DOI
  23. Van Dam, 1997, Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures, Scand J Gastroenterol, 32, 77, 10.3109/00365529709025067 · DOI
  24. Ahrens, 1949, The relationship between serum lipids and skin xanthomata in 18 patients with primary biliary cirrhosis, J Clin Invest, 28, 1565, 10.1172/JCI102222 · DOI
  25. Kamisako, 1995, Marked improvement in cholestasis and hypercholesterolemia with simvastatin in a patient with primary biliary cirrhosis, Am J Gastroenterol, 90, 1187
  26. Kurihara, 1993, Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia, Clin Ther, 15, 890
  27. Del Puppo, 2001, Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration, J Lipid Res, 42, 437, 10.1016/S0022-2275(20)31668-0 · DOI
  28. Anfossi, 2004, Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits, Nutr Metab Cardiovasc Dis, 14, 215, 10.1016/S0939-4753(04)80008-5 · DOI
  29. Ballare, 1991, Acute cholestatic hepatitis during simvastatin administration, Recent Prog Med, 82, 233
  30. Huchzermeyer, 1995, Lovastatin-induced acute cholestatic hepatitis, Dtsch Med Wochenschr, 120, 252, 10.1055/s-2008-1055341 · DOI
  31. Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006. · DOI · Paper page
  32. Levy, 2003, Management of primary biliary cirrhosis, Curr Treat Opt Gastroenterol, 6, 493, 10.1007/s11938-003-0051-4 · DOI
  33. Kurihara, 2000, Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid, Am J Gastroenterol, 95, 2990, 10.1111/j.1572-0241.2000.03220.x · DOI
  34. Dohmen, 2004, Fenofibrate for patients with asymptomatic primary biliary cirrhosis, World J Gastroenterol, 10, 894, 10.3748/wjg.v10.i6.894 · DOI · Paper page
  35. Kurihara, 2002, Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy, Am J Gastroenterol, 97, 212, 10.1111/j.1572-0241.2002.05413.x · DOI
  36. Balan, 1994, Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis, Mayo Clin Proc, 69, 923, 10.1016/S0025-6196(12)61815-1 · DOI · Paper page
  37. Roda, 1994, Influence of ursodeoxycholic acid on biliary lipids, Scand J Gastroenterol Suppl, 204, 16, 10.3109/00365529409103619 · doi:10.3109/00365529409103619
  38. Stiehl, 1990, Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids, Gastroenterology, 98, 424, 10.1016/0016-5085(90)90834-N · DOI
  39. Fromm, 1989, Bile acid–lipoprotein interactions: effects of ursodeoxycholic acid (ursodiol), Digest Dis Sci, 34, 21S, 10.1007/BF01536658 · DOI
  40. Salen, 1980, Effect of high and low doses of ursodeoxycholic acid on gallstone dissolution in humans, Gastroenterology, 78, 1412, 10.1016/S0016-5085(19)30493-7 · DOI
  41. Tint, 1986, Effect of ursodeoxycholic acid and chenodeoxycholic acid on cholesterol and bile acid metabolism, Gastroenterology, 91, 1007, 10.1016/0016-5085(86)90708-0 · DOI

Cited by

See all 167

Metadata

Authors
Sorokin, A., Brown, J. L., & Thompson, P. D.
Venue
Atherosclerosis
Publisher
Elsevier BV
Published
2007-10
Volume
194
Issue
2
Pages
293-299
ISSN
0021-9150 (ISSN-L)
OpenAlex
W1978946102
Cited by
167
References
6
FWCI
0.90
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review. https://app.cochat.ai/papers/10.1016/j.atherosclerosis.2006.11.036
The paper
Sorokin, A., Brown, J. L., & Thompson, P. D. (2007). Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: A systematic review. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2006.11.036

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.